Emerging evidence from preclinical and clinical studies supports the beneficial effects of CETP inhibitors and recombinant HDL-C (rHDL) particles in treating inflammatory diseases, improving glucose metabolism, and potentially combating certain cancers [20,21]. The gene discussed is CETP; the disease is cancer.